Homeobox gene expression profile indicates HOXA5 as a candidate prognostic marker in oral squamous cell carcinoma
Carregando...
Citações na Scopus
30
Tipo de produção
article
Data de publicação
2012
Editora
SPANDIDOS PUBL LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
RODINI, Camila Oliveira
XAVIER, Flavia Calo Aquino
PAIVA, Katiucia Batista Silva
DESTRO, Maria Fernanda De Souza Setubal
CARVALHO, Marcos Brasilino
FUKUYAMA, Erica Erina
TAJARA, Eloiza Helena
OKAMOTO, Oswaldo Keith
Autor de Grupo de pesquisa
Head Neck Genome Project Gencapo
Editores
Coordenadores
Organizadores
Citação
INTERNATIONAL JOURNAL OF ONCOLOGY, v.40, n.4, p.1180-1188, 2012
Resumo
The search for molecular markers to improve diagnosis, individualize treatment and predict behavior of tumors has been the focus of several studies. This study aimed to analyze homeobox gene expression profile in oral squamous cell carcinoma (OSCC) as well as to investigate whether some of these genes are relevant molecular markers of prognosis and/or tumor aggressiveness. Homeobox gene expression levels were assessed by microarrays and qRT-PCR in OSCC tissues and adjacent non-cancerous matched tissues (margin), as well as in OSCC cell lines. Analysis of microarray data revealed the expression of 147 homeobox genes, including one set of six at least 2-fold up-regulated, and another set of 34 at least 2-fold down-regulated homeobox genes in OSCC. After qRT-PCR assays, the three most up-regulated homeobox genes (HOXA5, HOXD10 and HOXD11) revealed higher and statistically significant expression levels in OSCC samples when compared to margins. Patients presenting lower expression of HOXA5 had poorer prognosis compared to those with higher expression (P=0.03). Additionally, the status of HOXA5, HOXD10 and HOXD11 expression levels in OSCC cell lines also showed a significant up-regulation when compared to normal oral keratinocytes. Results confirm the presence of three significantly upregulated (>4-fold) homeobox genes (HOXA5, HOXD10 and HOXD11) in OSCC that may play a significant role in the pathogenesis of these tumors. Moreover, since lower levels of HOXA5 predict poor prognosis, this gene may be a novel candidate for development of therapeutic strategies in OSCC.
Palavras-chave
oral cancer, homeobox genes, HOXA5, prognosis
Referências
- Al-Rajhi N, 2000, ORAL ONCOL, V36, P508, DOI 10.1016/S1368-8375(00)00042-7
- Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048
- Bello IO, 2010, ORAL ONCOL, V46, P636, DOI 10.1016/j.oraloncology.2010.06.008
- Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
- Cai LY, 2007, LIFE SCI, V80, P1458, DOI 10.1016/j.lfs.2007.01.015
- Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717
- Charoenrat P, 2003, ORAL ONCOL, V39, P386
- Chen HX, 2007, CANCER RES, V67, P8007, DOI 10.1158/0008-5472.CAN-07-1405
- Chen KN, 2005, CLIN CANCER RES, V11, P1044
- Choi S, 2008, J DENT RES, V87, P14
- Cillo C, 1996, INT J CANCER, V66, P692, DOI 10.1002/(SICI)1097-0215(19960529)66:5<692::AID-IJC18>3.0.CO;2-6
- Destro MFDS, 2010, INT J ONCOL, V36, P141, DOI 10.3892/ijo_00000485
- Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157
- Greene FL, 2009, J SURG ONCOL, V99, P269, DOI 10.1002/jso.21237
- Hassan NMM, 2006, ONCOL RES, V16, P217
- Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
- Kim DS, 2009, MOL CARCINOGEN, V48, P1109, DOI 10.1002/mc.20561
- Klingbeil MFG, 2009, CELL TISSUE BANK, V10, P197, DOI 10.1007/s10561-009-9122-7
- Kuo Winston Patrick, 2003, N Y State Dent J, V69, P23
- Lechner JF, 2001, RADIAT RES, V155, P235, DOI 10.1667/0033-7587(2001)155[0235:PCDTMA]2.0.CO;2
- Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49
- Lopez R, 2006, INT J GYNECOL CANCER, V16, P329, DOI 10.1111/j.1525-1438.2006.00350.x
- Mendez LE, 2002, GYNECOL ONCOL, V86, P138, DOI 10.1006/gyno.2002.6745
- Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
- Nagai H, 2003, GENE CHROMOSOME CANC, V38, P13, DOI 10.1002/gcc.10248
- Nagai H, 1999, GENE CHROMOSOME CANC, V25, P277, DOI 10.1002/(SICI)1098-2264(199907)25:3<277::AID-GCC10>3.3.CO;2-C
- Okamoto M, 2002, J ORAL PATHOL MED, V31, P227, DOI 10.1034/j.1600-0714.2002.310406.x
- Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
- Perez-Sayans M, 2009, ONCOL REP, V22, P1277, DOI 10.3892/or_00000565
- Raman V, 2000, NATURE, V405, P974
- Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200
- Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103
- Rossi Degl'Innocenti Duccio, 2007, Int J Mol Med, V20, P621
- Rubin E, 2007, CANCER RES, V67, P1527, DOI 10.1158/0008-5475.CAN-06-4283
- Saeed AI, 2003, BIOTECHNIQUES, V34, P374
- Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
- Severino Patricia, 2008, BMC Res Notes, V1, P113, DOI 10.1186/1756-0500-1-113
- Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
- Shimoda M, 2006, CLIN CANCER RES, V12, P6005, DOI 10.1158/1078-0432.CCR-06-0712
- SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
- Svingen T, 2006, HEREDITY, V97, P88, DOI 10.1038/sj.hdy.6800847
- Takahashi O, 2007, ONCOL REP, V17, P753
- Takahashi Y, 2004, EXP CELL RES, V293, P144, DOI 10.1016/j.yexcr.2003.09.024
- TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426
- Turan N, 2010, EPIGENETICS-US, V5, P16
- Woolgar JA, 2006, ORAL ONCOL, V42, P229, DOI 10.1016/j.oraloncology.2005.05.008
- World Health Organization, 2005, PATH GEN HEAD NECK T
- Wu JY, 2010, ORAL ONCOL, V46, P226, DOI 10.1016/j.oraloncology.2010.01.007
- Yamatoji M, 2010, ONCOL REP, V23, P61, DOI 10.3892/or_00000606
- Yang YC, 2009, EUR J GASTROEN HEPAT, V21, P1016, DOI 10.1097/MEG.0b013e32831d7b9c
- Zhou Shi-xin, 2004, Yichuan, V26, P984
- Zhu F, 2004, J BIOCHEM MOL BIOL, V37, P671
- Ziober AF, 2006, CLIN CANCER RES, V12, P5960, DOI 10.1158/1078-0432.CCR-06-0535